FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310093223> ?p ?o ?g. }

• W4310093223 endingPage "3561" @default.
• W4310093223 startingPage "3559" @default.
• W4310093223 abstract "Background: Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare B-cell malignancy characterized by infrequent neoplastic cells embedded in an immunologically active tumor microenvironment (TME). Histologically, NLPHL can be divided into classical (Fan A-B) and variant (Fan C-F) growth patterns. Clinical course is generally indolent, and the majority of patients present with limited stage disease. However, advanced stage with splenic involvement and variant histology are known to be associated with more aggressive disease. The molecular features underlying this association remain unknown. To gain further insights into disease biology, we recruited NLPHL cases as part of the Atlas of Blood Cancer Genomes (ABCG) initiative, a consortium consisting of 26 institutions. Design: We collected comprehensive clinicopathological data including splenic involvement from 135 NLPHL patients, with centralized review performed by a panel of dedicated hematopathologists to ensure accurate diagnosis per 2016 WHO criteria. We performed RNA sequencing on formalin-fixed paraffin-embedded (FFPE) diagnostic tumor lymph nodes (n=100) and enumerated tumor-infiltrating immune cell compositions using FARDEEP with signature matrix LM22 from CIBERSORT. In addition, we performed gene set enrichment analysis to compare molecular pathways between the patients with and without splenic involvement. The Kaplan-Meier method was used to calculate overall survival (OS) and progression free survival (PFS) probabilities, and the log-rank test was used for comparisons between groups. Continuous variables were compared using the Wilcoxon rank-sum test. Results: The median age at diagnosis was 42 years (range 5-80 years). Most patients were males (n=96; 71%) and had limited stage disease (n=96, 74%). Splenic involvement was present in 17 patients (13%). Histologic growth pattern was available for 97 cases, 41 (42%) with variant and 56 (58%) with classical histology. Variant histology was enriched in the patients with splenic involvement. Thirty-five (28%) relapses and 5 (3.9%) transformations occurred during a median follow-up of 80 months (range 0.36-604 months). Ten-year OS and PFS rates for the whole cohort were 86% (95% CI, 78-95%) and 59% (95% CI, 50-71%), respectively. Patients with splenic involvement at diagnosis tended to have inferior outcome at 10 years compared with those without splenic involvement (PFS 40% vs 62%, P=0.129; OS 79% vs 88%, P=0.0553). According to in silico immunophenotyping, NLPHLs with splenic involvement were characterized by a lower proportion of naïve B cells and increased proportions of CD8+ T cells and M1-macrophages compared to the NLPHLs without splenic involvement (P<0.001 for all comparisons). Moreover, splenic involvement was associated with higher expression of checkpoint protein-encoding genes, including PDCD1 (PD-1), CD274 (PD-L1), CTLA4, LAG3, HAVCR2 (TIM-3) and TIGIT (Figure 1; P<0.001). Finally, we found a strong association between splenic involvement and gene expression profile related to inflammatory response (P<0.001), response to interferon gamma (P<0.001) and complement pathways (P<0.001). Conclusion: Our study represents the largest comprehensive clinical and transcriptomic analyses of NLPHL to date. The results demonstrate that NLPHLs with splenic involvement are characterized by inflamed TME with high expression of checkpoint molecule gene-signature and are associated with inferior outcomes. Figure 1. Unsupervised clustering for expression of checkpoint genes stratified by spleen involvement. Samples are ordered by the sum of normalized checkpoint gene expression values (checkpoint score) Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310093223 created "2022-11-30" @default.
• W4310093223 creator A5003867655 @default.
• W4310093223 creator A5005168764 @default.
• W4310093223 creator A5006583715 @default.
• W4310093223 creator A5008328996 @default.
• W4310093223 creator A5008671495 @default.
• W4310093223 creator A5009137826 @default.
• W4310093223 creator A5009508059 @default.
• W4310093223 creator A5010756701 @default.
• W4310093223 creator A5013263576 @default.
• W4310093223 creator A5025928549 @default.
• W4310093223 creator A5026011719 @default.
• W4310093223 creator A5026502155 @default.
• W4310093223 creator A5027080346 @default.
• W4310093223 creator A5030353708 @default.
• W4310093223 creator A5031238770 @default.
• W4310093223 creator A5031551892 @default.
• W4310093223 creator A5040843582 @default.
• W4310093223 creator A5045622683 @default.
• W4310093223 creator A5045914250 @default.
• W4310093223 creator A5047318164 @default.
• W4310093223 creator A5051888634 @default.
• W4310093223 creator A5052305733 @default.
• W4310093223 creator A5055183115 @default.
• W4310093223 creator A5064643006 @default.
• W4310093223 creator A5064702056 @default.
• W4310093223 creator A5064738578 @default.
• W4310093223 creator A5069657770 @default.
• W4310093223 creator A5071505679 @default.
• W4310093223 creator A5073065181 @default.
• W4310093223 creator A5073890024 @default.
• W4310093223 creator A5075581216 @default.
• W4310093223 creator A5076303500 @default.
• W4310093223 creator A5080038116 @default.
• W4310093223 creator A5080939807 @default.
• W4310093223 creator A5081219793 @default.
• W4310093223 creator A5083592086 @default.
• W4310093223 creator A5084525969 @default.
• W4310093223 creator A5087061397 @default.
• W4310093223 creator A5088101785 @default.
• W4310093223 creator A5088958720 @default.
• W4310093223 creator A5089994358 @default.
• W4310093223 creator A5091838077 @default.
• W4310093223 date "2022-11-15" @default.
• W4310093223 modified "2023-10-17" @default.
• W4310093223 title "Nodular Lymphocyte Predominant Hodgkin Lymphoma with Splenic Involvement Is Characterized By Inflamed Tumor Microenvironment, High Expression of Checkpoint Molecule Gene-Signature and Adverse Outcome" @default.
• W4310093223 doi "https://doi.org/10.1182/blood-2022-169476" @default.
• W4310093223 hasPublicationYear "2022" @default.
• W4310093223 type Work @default.
• W4310093223 citedByCount "0" @default.
• W4310093223 crossrefType "journal-article" @default.
• W4310093223 hasAuthorship W4310093223A5003867655 @default.
• W4310093223 hasAuthorship W4310093223A5005168764 @default.
• W4310093223 hasAuthorship W4310093223A5006583715 @default.
• W4310093223 hasAuthorship W4310093223A5008328996 @default.
• W4310093223 hasAuthorship W4310093223A5008671495 @default.
• W4310093223 hasAuthorship W4310093223A5009137826 @default.
• W4310093223 hasAuthorship W4310093223A5009508059 @default.
• W4310093223 hasAuthorship W4310093223A5010756701 @default.
• W4310093223 hasAuthorship W4310093223A5013263576 @default.
• W4310093223 hasAuthorship W4310093223A5025928549 @default.
• W4310093223 hasAuthorship W4310093223A5026011719 @default.
• W4310093223 hasAuthorship W4310093223A5026502155 @default.
• W4310093223 hasAuthorship W4310093223A5027080346 @default.
• W4310093223 hasAuthorship W4310093223A5030353708 @default.
• W4310093223 hasAuthorship W4310093223A5031238770 @default.
• W4310093223 hasAuthorship W4310093223A5031551892 @default.
• W4310093223 hasAuthorship W4310093223A5040843582 @default.
• W4310093223 hasAuthorship W4310093223A5045622683 @default.
• W4310093223 hasAuthorship W4310093223A5045914250 @default.
• W4310093223 hasAuthorship W4310093223A5047318164 @default.
• W4310093223 hasAuthorship W4310093223A5051888634 @default.
• W4310093223 hasAuthorship W4310093223A5052305733 @default.
• W4310093223 hasAuthorship W4310093223A5055183115 @default.
• W4310093223 hasAuthorship W4310093223A5064643006 @default.
• W4310093223 hasAuthorship W4310093223A5064702056 @default.
• W4310093223 hasAuthorship W4310093223A5064738578 @default.
• W4310093223 hasAuthorship W4310093223A5069657770 @default.
• W4310093223 hasAuthorship W4310093223A5071505679 @default.
• W4310093223 hasAuthorship W4310093223A5073065181 @default.
• W4310093223 hasAuthorship W4310093223A5073890024 @default.
• W4310093223 hasAuthorship W4310093223A5075581216 @default.
• W4310093223 hasAuthorship W4310093223A5076303500 @default.
• W4310093223 hasAuthorship W4310093223A5080038116 @default.
• W4310093223 hasAuthorship W4310093223A5080939807 @default.
• W4310093223 hasAuthorship W4310093223A5081219793 @default.
• W4310093223 hasAuthorship W4310093223A5083592086 @default.
• W4310093223 hasAuthorship W4310093223A5084525969 @default.
• W4310093223 hasAuthorship W4310093223A5087061397 @default.
• W4310093223 hasAuthorship W4310093223A5088101785 @default.
• W4310093223 hasAuthorship W4310093223A5088958720 @default.
• W4310093223 hasAuthorship W4310093223A5089994358 @default.
• W4310093223 hasAuthorship W4310093223A5091838077 @default.
• W4310093223 hasBestOaLocation W43100932231 @default.
• W4310093223 hasConcept C104317684 @default.
• W4310093223 hasConcept C142724271 @default.
• W4310093223 hasConcept C150194340 @default.

• next